Stephen L Seliger1, Susie N Hong1, Robert H Christenson1, Richard Kronmal1, Lori B Daniels1, Joao A C Lima1, James A de Lemos1, Alain Bertoni1, Christopher R deFilippi2. 1. From Division of Nephrology (S.L.S.), Division of Cardiovascular Medicine (S.N.H.), and Department of Pathology (R.H.C.), University of Maryland School of Medicine, Baltimore; University of Washington, Department of Biostatistics, Seattle (R.K.); University of California at San Diego, Division of Cardiology, La Jolla (L.B.D.); Johns Hopkins University, Division of Cardiology, Baltimore, MD (J.A.C.L.); University of Texas Southwestern Medical Center, Division of Cardiology, Dallas (J.A.d.L.); Wake Forest School of Medicine, Department of Epidemiology and Prevention, Winston-Salem, NC (A.B.); and Inova Heart and Vascular Institute, Falls Church, VA (C.R.d.). 2. From Division of Nephrology (S.L.S.), Division of Cardiovascular Medicine (S.N.H.), and Department of Pathology (R.H.C.), University of Maryland School of Medicine, Baltimore; University of Washington, Department of Biostatistics, Seattle (R.K.); University of California at San Diego, Division of Cardiology, La Jolla (L.B.D.); Johns Hopkins University, Division of Cardiology, Baltimore, MD (J.A.C.L.); University of Texas Southwestern Medical Center, Division of Cardiology, Dallas (J.A.d.L.); Wake Forest School of Medicine, Department of Epidemiology and Prevention, Winston-Salem, NC (A.B.); and Inova Heart and Vascular Institute, Falls Church, VA (C.R.d.). Christopher.Defilippi@inova.org.
Abstract
BACKGROUND: Although small elevations of high-sensitive cardiac troponin T (hs-cTnT) are associated with incident heart failure (HF) in the general population, the underlying mechanisms are not well defined. Evaluating the association of hs-cTnT with replacement fibrosis and progression of structural heart disease before symptoms is fundamental to understanding the potential of this biomarker in a HF prevention strategy. METHODS: We measured hs-cTnT at baseline among 4986 participants in MESA (Multi-Ethnic Study of Atherosclerosis), a cohort initially free of overt cardiovascular disease (CVD). Cardiac magnetic resonance imaging was performed at baseline. Repeat cardiac magnetic resonance was performed 10 years later among 2831 participants who remained free of interim CVD events; of these, 1723 received gadolinium-enhanced cardiac magnetic resonance for characterization of replacement fibrosis by late gadolinium enhancement. Progression of subclinical CVD was defined by 10-year change in left ventricular structure and function. Associations of hs-cTnT with incident HF, CV-related mortality, and coronary heart disease were estimated using Cox regression models. RESULTS: Late gadolinium enhancement for replacement fibrosis was detectable in 6.3% participants without interim CVD events by follow-up cardiac magnetic resonance. A graded association was observed between higher baseline hs-cTnT categories and late gadolinium enhancement (≥7.42 ng/L versus <limit of detection [<3 ng/L]; adjusted odds ratio, 2.87; 95% confidence interval, 1.38-5.94). Higher hs-cTnT was also associated with a greater probability of an increase in LV mass >12% (highest category versus <limit of detection; odds ratio, 1.50; 95% confidence interval, 1.09-2.07), but not with decline in left ventricular ejection fraction. The risk of incident HF was greater for higher hs-cTnT (≥8.81 ng/L versus <limit of detection; adjusted hazards ratio, 5.59; 95% CI, 2.97-10.68). CONCLUSIONS: hs-cTnT levels are associated with replacement fibrosis and progressive changes in left ventricular structure in CVD-free adults, findings that may precede HF symptoms by years. Minor elevations of hs-cTnT may represent a biochemical signature of early subclinical cardiac disease, providing an opportunity for targeted preventive interventions.
BACKGROUND: Although small elevations of high-sensitive cardiac troponin T (hs-cTnT) are associated with incident heart failure (HF) in the general population, the underlying mechanisms are not well defined. Evaluating the association of hs-cTnT with replacement fibrosis and progression of structural heart disease before symptoms is fundamental to understanding the potential of this biomarker in a HF prevention strategy. METHODS: We measured hs-cTnT at baseline among 4986 participants in MESA (Multi-Ethnic Study of Atherosclerosis), a cohort initially free of overt cardiovascular disease (CVD). Cardiac magnetic resonance imaging was performed at baseline. Repeat cardiac magnetic resonance was performed 10 years later among 2831 participants who remained free of interim CVD events; of these, 1723 received gadolinium-enhanced cardiac magnetic resonance for characterization of replacement fibrosis by late gadolinium enhancement. Progression of subclinical CVD was defined by 10-year change in left ventricular structure and function. Associations of hs-cTnT with incident HF, CV-related mortality, and coronary heart disease were estimated using Cox regression models. RESULTS: Late gadolinium enhancement for replacement fibrosis was detectable in 6.3% participants without interim CVD events by follow-up cardiac magnetic resonance. A graded association was observed between higher baseline hs-cTnT categories and late gadolinium enhancement (≥7.42 ng/L versus <limit of detection [<3 ng/L]; adjusted odds ratio, 2.87; 95% confidence interval, 1.38-5.94). Higher hs-cTnT was also associated with a greater probability of an increase in LV mass >12% (highest category versus <limit of detection; odds ratio, 1.50; 95% confidence interval, 1.09-2.07), but not with decline in left ventricular ejection fraction. The risk of incident HF was greater for higher hs-cTnT (≥8.81 ng/L versus <limit of detection; adjusted hazards ratio, 5.59; 95% CI, 2.97-10.68). CONCLUSIONS:hs-cTnT levels are associated with replacement fibrosis and progressive changes in left ventricular structure in CVD-free adults, findings that may precede HF symptoms by years. Minor elevations of hs-cTnT may represent a biochemical signature of early subclinical cardiac disease, providing an opportunity for targeted preventive interventions.
Authors: Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger Journal: JAMA Date: 2010-11-15 Impact factor: 56.272
Authors: Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke Journal: AJR Am J Roentgenol Date: 2006-06 Impact factor: 3.959
Authors: Eui-Young Choi; Hossein Bahrami; Colin O Wu; Philip Greenland; Mary Cushman; Lori B Daniels; Andre L C Almeida; Kihei Yoneyama; Anders Opdahl; Aditya Jain; Michael H Criqui; David Siscovick; Christine Darwin; Alan Maisel; David A Bluemke; Joao A C Lima Journal: Circ Heart Fail Date: 2012-10-02 Impact factor: 8.790
Authors: Lori B Daniels; Paul Clopton; Christopher R deFilippi; Otto A Sanchez; Hossein Bahrami; Joao A C Lima; Russell P Tracy; David Siscovick; Alain G Bertoni; Philip Greenland; Mary Cushman; Alan S Maisel; Michael H Criqui Journal: Am Heart J Date: 2015-09-28 Impact factor: 4.749
Authors: Raymond Y Kwong; Hamid Sattar; Henry Wu; Gabriel Vorobiof; Vijay Gandla; Kevin Steel; Samuel Siu; Kenneth A Brown Journal: Circulation Date: 2008-08-25 Impact factor: 29.690
Authors: Evrim B Turkbey; Marcelo S Nacif; Mengye Guo; Robyn L McClelland; Patricia B R P Teixeira; Diane E Bild; R Graham Barr; Steven Shea; Wendy Post; Gregory Burke; Matthew J Budoff; Aaron R Folsom; Chia-Ying Liu; João A Lima; David A Bluemke Journal: JAMA Date: 2015-11-10 Impact factor: 56.272
Authors: Erik B Schelbert; Jie J Cao; Sigurdur Sigurdsson; Thor Aspelund; Peter Kellman; Anthony H Aletras; Christopher K Dyke; Gudmundur Thorgeirsson; Gudny Eiriksdottir; Lenore J Launer; Vilmundur Gudnason; Tamara B Harris; Andrew E Arai Journal: JAMA Date: 2012-09-05 Impact factor: 56.272
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Ambarish Pandey; Neil Keshvani; Colby Ayers; Adolfo Correa; Mark H Drazner; Alana Lewis; Carlos J Rodriguez; Michael E Hall; Ervin R Fox; Robert J Mentz; Christopher deFilippi; Stephen L Seliger; Christie M Ballantyne; Ian J Neeland; James A de Lemos; Jarett D Berry Journal: JAMA Cardiol Date: 2019-01-01 Impact factor: 14.676
Authors: Kwok-Leung Ong; Robyn L McClelland; Matthew A Allison; John Kokkinos; Ben J Wu; Philip J Barter; Kerry-Anne Rye Journal: Atherosclerosis Date: 2018-10-17 Impact factor: 5.162
Authors: Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Kavita Sharma; Sanjiv J Shah; Susan R Heckbert; Joao A Lima; Christopher R deFilippi; Matthew J Budoff; Wendy S Post; Erin D Michos Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Ambarish Pandey; Kershaw V Patel; Wanpen Vongpatanasin; Colby Ayers; Jarett D Berry; Robert J Mentz; Michael J Blaha; John W McEvoy; Paul Muntner; Muthiah Vaduganathan; Adolfo Correa; Javed Butler; Daichi Shimbo; Vijay Nambi; Christopher deFilippi; Stephen L Seliger; Christie M Ballantyne; Elizabeth Selvin; James A de Lemos; Parag H Joshi Journal: Circulation Date: 2019-11-11 Impact factor: 29.690
Authors: Alana A Lewis; Colby R Ayers; Elizabeth Selvin; Ian Neeland; Christie M Ballantyne; Vijay Nambi; Ambarish Pandey; Tiffany M Powell-Wiley; Mark H Drazner; Mercedes R Carnethon; Jarett D Berry; Stephen L Seliger; Christopher R DeFilippi; James A de Lemos Journal: Circulation Date: 2020-01-14 Impact factor: 29.690
Authors: Yejin Mok; Yingying Sang; Shoshana H Ballew; Ron C Hoogeveen; Christie M Ballantyne; Wayne Rosamond; Josef Coresh; Elizabeth Selvin; Kunihiro Matsushita Journal: Am Heart J Date: 2019-07-13 Impact factor: 4.749